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Abstract
Combination estrogen plus progestin causes breast cancer. In
light of this causal relation, the rapid decline in breast cancer
incidence noted in 2003, following an earlier and slower reduction
in incidence from 1999, raises important issues regarding the
proportion of this decline that may be due to a reduction in the use
of combination therapy by postmenopausal women. The context of
these national trends is reviewed and the strong link to the use of
hormone therapy is discussed, after noting that screening cannot
explain any substantial component of these trends. The rapid
decrease in incidence, most evident among women aged 50 to
69 years and in estrogen receptor positive tumors, that parallels
the decline in combination hormone use is consistent with a
promoter effect for estrogen plus progestins.
A rigorous analysis of Surveillance, Epidemiology, and End
Results (SEER) data [1], addressing trends on breast cancer
incidence, tumor characteristics, and patterns of incidence for
in situ cancer, added new insights into the impact that
combination hormone therapy has on risk for breast cancer at
the population level. Combination therapy (estrogen plus
progestin [E&P]) causes breast cancer and is classified as a
carcinogen by the International Agency for Research on
Cancer [2]. Here, I address how much of the recently reported
decrease in incidence [1] is due to a reduction in the use of
combination E&P postmenopausal hormone therapy.
The association of unopposed estrogen with endometrial
cancer provides strong evidence that hormone therapy can
act as a late promoter of cancer. With the acknowledgment
of the causal relation in the 1970s, a sharp decline in
estrogen prescribing led to a parallel rapid decrease in
incidence of endometrial cancer [3]. Uptake of E&P therapy
was somewhat slow, and epidemiologic data in the USA
were limited in their ability to separate effects of combination
therapy from those of unopposed estrogen. However, by
1995 prospective data indicated that E&P therapy did not
protect against breast cancer and that the increase in risk
may be greater than for estrogen alone [4]. Although
estrogen alone remained the treatment of choice for women
without a uterus, between the mid-1970s and the mid-1980s
surveillance data showed that the incidence of estrogen
receptor positive tumors increased by an average of 131% in
the population-based tumor registry of Kaiser Permanente in
the USA (Portland, OR) [5], perhaps implicating the
involvement of hormonal factors in the rising incidence of
breast cancer.
Population-based epidemiologic studies [6] and cohort data
[7] matured during the latter 1990s to show that combination
E&P therapy significantly increased risk, and that this was
most evident among leaner women. Recommendations based
on these findings were that women should avoid progestins if
possible [8]. A broad range of epidemiologic studies
continue to support the causal relation between combination
E&P and total breast cancer. Meanwhile, some investigators
have focused on the increase in lobular cancer [9,10]; the
clear estrogen receptor positive nature of these lobular
tumors, as compared with ductal tumors, which are receptor
positive to a lesser extent, provides a clearer indication that
this subset of tumors is caused by combination E&P. Studies
of receptor positive tumors show that combination therapy
clearly increases risk [5].
In 2002, the Women’s Health Initiative (WHI) confirmed the
epidemiologic findings relating combination hormone therapy
to increased risk for breast cancer. Despite substantial non-
Editorial
Decline in breast cancer incidence due to removal of promoter:
combination estrogen plus progestin
Graham A Colditz
Alvin J Siteman Cancer Center and Department of Surgery, Washington University School of Medicine, Campus Box 8100 660 S Euclid Avenue,
St Louis, MO 63110, USA
Corresponding author: Graham A Colditz, colditzg@wustl.edu
Published: 26 July 2007 Breast Cancer Research 2007, 9:108 (doi:10.1186/bcr1736)
This article is online at http://breast-cancer-research.com/content/9/4/108
© 2007 BioMed Central Ltd
See related research article by Jemal et al.,  http://breast-cancer-research.com/content/9/3/R28
E&P = estrogen plus progestin; HER = Heart and Estrogen/Progestin Replacement Study; PAR = population attributable risk; SEER = Surveil-
lance, Epidemiology, and End Results; WHI = Women’s Health Initiative.Page 2 of 3
(page number not for citation purposes)
Breast Cancer Research    Vol 9 No 4 Colditz
adherence to therapy, which exceeded 40% among women
randomly assigned to E&P, the predetermined stopping rules
for the WHI led the independent data safety monitoring board
to stop the trial early because of the adverse effect of therapy
on breast cancer [11]. The intention to treat and, more
importantly, the adherence-based relative risks (which
approximate the relative risks from epidemiologic studies that
record use and nonuse of therapy) were consistent with the
Heart and Estrogen/Progestin Replacement Study (HERS)
trial [12] and epidemiologic data showing an increase in risk
in the initial 2 to 5 years of use. Furthermore, risk increased
significantly with duration of therapy.
Based on data from the San Francisco mammography
registry, prescribing of E&P peaked in 1999. The use of
hormone therapy was increasing at 1% per quarter before
publication of the HERS report, but it declined by 1% per
quarter after publication [13]. This decline in prescribing
continued until the publication of the WHI in 2002, after
which a more substantial decline of 18% per quarter was
observed. The peak and decline through 1999 to 2002 is
concordant with the HERS report in 1998 [12], which found
a significant increase in coronary heart disease during the
first year of therapy among women with prevalent coronary
disease and, in addition, no long-term benefit in reducing
coronary heart disease [14]. The growing epidemiologic
evidence published since 2000 on the adverse effects of
combination therapy on breast cancer added further support
to avoid its use. Considering the prevalence of use of E&P in
California, Clarke and coworkers [15] estimated a population
attributable risk (PAR, or the proportion of cases caused by
E&P) of up to 11%, based on a prevalence of use of 30%
and a relative risk of 1.4. Given that substantially greater
relative risks of 2 or higher have been reported [16], this
estimated PAR may be conservative. Assuming a prevalence
of use of 17.5% (the average reported for California in 2001
[15]), a relative risk of 1.49 gives a PAR of 7.9% and a
relative risk of 2.0 gives a PAR of 14.9%.
Evidence regarding breast cancer incidence rates now clearly
shows a parallel drop in breast cancer consistent with the
pattern of decreased prescribing. Jemal and coworkers [1]
conducted a rigorous, state-of-the-art analysis using joint
point analysis and drawing on SEER incidence data from
1975 through to 2003. They demonstrated a significant
decrease in the incidence of invasive breast cancer from
1999 to 2003 in all 5-year age groups from 45 years and
above, and a sharp decrease largely limited to estrogen
receptor positive tumors in age groups from 50 to 69
between 2002 and 2003. Furthermore, although others have
suggested that a 1% to 3% drop in screening mammography
may account for this decline in incidence, Jemal and
coworkers provided strong evidence against this contention.
If screening were to account for a drop in incidence, then
rates of in situ disease would also need to drop because they
are almost only detected by mammography. Jemal and
coworkers demonstrated that, before screening became
widespread, in situ rates were low and rose with the uptake
of screening to plateau from 1999 through to 2003. The lack
of a drop in in situ cancer offers compelling evidence that a
reduction in screening does not account for the drop in
incidence of invasive breast cancer.
Others have analyzed SEER data over a shorter period [17]
or draw on the unique resources of the California tumor
registry and health maintenance organization datasets [18] to
show similar relations between change in hormone therapy
and a decrease in breast cancer incidence. Most recently,
Robbins and Clarke [19] evaluated the change in prescribing,
as estimated from the California Health Interview Survey,
among almost three million non-Hispanic white women aged
45 to 74 years, and compared the findings with the change in
breast cancer incidence across 58 counties in California.
This thoughtful analysis shows that, from 2001 to 2004, the
incidence of breast cancer declined by 8.8% in the counties
with the smallest E&P reductions, by 13.9% in those with
intermediate reductions, and by 22.6% in counties with the
greatest reductions in combination postmenopausal hormone
therapy. Between 2001 and 2003, California Health Interview
Survey data did not indicate any significant change in the
proportion of women who reported having a mammogram
during the previous 2 years, adding further evidence against
this as a plausible major explanatory factor for the observed
declines in breast cancer incidence. Even more evidence in
support of this relation between decrease in E&P prescribing
and breast cancer comes from declines in incidence reported
in New Zealand [20] and Germany [21] that parallel those in
the USA.
Trends in obesity in the USA run counter to the decline in
breast cancer incidence, the genetic make up of the
population has not changed, and there has been a dramatic
decline in breast cancer incidence in the USA that is largely
confined to estrogen receptor positive tumors, along with
similar declines documented in other countries. Given these
findings, the evidence unarguably indicates that there is a
causal relation between this abrupt reduction in use of E&P
hormone therapy and the decline in breast cancer. The public
health impact of this must not be underestimated. In fact, this
decrease, amounting to approximately 10,000 fewer cases,
falls within the range of attributable risk estimates for beast
cancer due to E&P, suggesting that these estimates are
conservative because not all women have ceased using
combination therapy.
Although research issues remain, for instance regarding
impact of dose of progestin per month on risk for breast
cancer, women should be reassured that these data support
a rapid risk reduction following cessation of therapy with E&P.
Long-term use may yet cause some residual increase in risk
[22]. Finer analysis that accounts for duration of prior use
may resolve this issue.Page 3 of 3
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